Methotrexate use, not interleukin 33, is associated with lower carotid intima-media thickness in patients with rheumatoid arthritis.

Autor: Pinto MRC; School of Medicine, Federal University of Minas Gerais (Universidade Federal de Minas Gerais - UFMG), Avenida Alfredo Balena, 190, Bairro Santa Efigênia, Belo Horizonte, Minas Gerais, CEP 30130-100, Brazil. dramariaraquel@gmail.com., Kakehasi AM; School of Medicine, Federal University of Minas Gerais (Universidade Federal de Minas Gerais - UFMG), Avenida Alfredo Balena, 190, Bairro Santa Efigênia, Belo Horizonte, Minas Gerais, CEP 30130-100, Brazil., Souza AJ; Conrad Diagnostic Imaging (Conrad Diagnóstico por Imagem), Rua Rio Grande do Norte, 77, Bairro Santa Efigênia, Belo Horizonte, MG, CEP: 30130-130, Brazil., Tavares WC Jr; Ecoar Diagnostic Medicine (Ecoar Medicina Diagnóstica), Avenida do Contorno, 6760, Bairro Santo Antônio, Belo Horizonte, MG, CEP: 30110-044, Brazil., Rocha MA; School of Medicine, Federal University of Minas Gerais (Universidade Federal de Minas Gerais - UFMG), Avenida Alfredo Balena, 190, Bairro Santa Efigênia, Belo Horizonte, Minas Gerais, CEP 30130-100, Brazil., Trant CGMC; School of Medicine, Federal University of Minas Gerais (Universidade Federal de Minas Gerais - UFMG), Avenida Alfredo Balena, 190, Bairro Santa Efigênia, Belo Horizonte, Minas Gerais, CEP 30130-100, Brazil., Andrade MV; School of Medicine, Federal University of Minas Gerais (Universidade Federal de Minas Gerais - UFMG), Avenida Alfredo Balena, 190, Bairro Santa Efigênia, Belo Horizonte, Minas Gerais, CEP 30130-100, Brazil.
Jazyk: angličtina
Zdroj: Advances in rheumatology (London, England) [Adv Rheumatol] 2019 Apr 03; Vol. 59 (1), pp. 15. Date of Electronic Publication: 2019 Apr 03.
DOI: 10.1186/s42358-019-0060-1
Abstrakt: Background: Rheumatoid arthritis is a risk factor for early mortality due to cardiovascular disease. Interleukin-33 appears to protect against the development of atherosclerosis. The purpose of this study was to investigate the relationship between serum levels of interleukin-33 and its soluble receptor with the presence of subclinical carotid atherosclerosis in rheumatoid arthritis patients.
Methods: Rheumatoid arthritis patients without atherosclerotic disease were subjected to clinical and laboratory assessments, including carotid ultrasound. Interleukin-33 and its soluble receptor serum levels were measured by ELISA.
Results: 102 patients were included. The prevalence of carotid plaques was 23.5% and the median intima-media thickness was 0.7 mm. The median interleukin-33 and its soluble receptor concentration was 69.1 and 469.8 pg/ml. No association was found between serum interleukin-33 or its soluble receptor and intima-media thickness or plaque occurrence. Each 0.1 mm increase of intima-media thickness raised the odds of plaque occurrence by 5.3-fold, and each additional year of rheumatoid arthritis duration increased the odds of plaque occurrence by 6%. Each additional year in patients age and each one-point increase in the Framingham Risk Score were associated with a 0.004 mm and 0.012 mm increase in intima-media thickness. Methotrexate use was associated with a 0.07 mm reduction in intima-media thickness.
Conclusions: Interleukin-33 and its soluble receptor were not associated with subclinical atherosclerosis. Traditional risk factors for atherosclerosis and rheumatoid arthritis duration were associated with intima-media thickness and plaque occurrence; methotrexate use was associated with a lower intima-media thickness.
Databáze: MEDLINE
Externí odkaz: